Evidence map›Paper›PMID 37652990›Full record

SynthesisScientific reports2023

Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials.

Stephanie J Loomis, Nilanjana Sadhu, Elizabeth Fisher, Arie R Gafson, Yunfeng Huang, Chengran Yang, Emily E Hughes, Eric Marshall, Ann Herman, Sally John and 4 more

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Stephanie J Loomis *Biogen, Cambridge, MA, USA. stephanie.loomis@biogen.com.
Nilanjana Sadhu *Biogen, Cambridge, MA, USA.
Elizabeth FisherBiogen, Cambridge, MA, USA.
Arie R GafsonBiogen, Cambridge, MA, USA.
Yunfeng HuangBiogen, Cambridge, MA, USA.
Chengran YangBiogen, Cambridge, MA, USA.
Emily E HughesBiogen, Cambridge, MA, USA.
Eric MarshallBiogen, Cambridge, MA, USA.
Ann HermanGenentech, South San Francisco, CA, USA.
Sally JohnBiogen, Cambridge, MA, USA.
Heiko RunzBiogen, Cambridge, MA, USA.
Xiaoming JiaGenentech, South San Francisco, CA, USA.
Tushar BhangaleGenentech, South San Francisco, CA, USA.
Paola G BronsonBiogen, Cambridge, MA, USA.
Biogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the genetics of MS risk susceptibility are well-described, and recent progress has been made on the genetics of disease severity, the genetics of disease progression remain elusive. We therefore investigated the genetic determinants of MS progression on longitudinal brain MRI: change in brain volume (BV) and change in T2 lesion volume (T2LV), reflecting progressive tissue loss and increasing disease burden, respectively. We performed genome-wide association studies of change in BV (N = 3401) and change in T2LV (N = 3513) across six randomized clinical trials from Biogen and Roche/Genentech: ADVANCE, ASCEND, DECIDE, OPERA I & II, and ORATORIO. Analyses were adjusted for randomized treatment arm, age, sex, and ancestry. Results were pooled in a meta-analysis, and were evaluated for enrichment of MS risk variants. Variant colocalization and cell-specific expression analyses were performed using published cohorts. The strongest peaks were in PTPRD (rs77321193-C/A, p = 3.9 × 10

Indexed as

BrainGenome-Wide Association StudyMultiple SclerosisCost of IllnessDisease ProgressionHumansNeuroimagingRandomized Controlled Trials as Topic

Identifiers

PMID37652990
PMCPMC10471679
OpenAlexW4386324853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.